Can simple tests predict dangerous lung side effects in cancer patients?

NCT ID NCT04913311

Recruiting now Knowledge-focused Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 12, 2026 · Updated 3 times

Summary

This study tracks 150 people with non-small cell lung cancer who are getting chemotherapy and radiation followed by immunotherapy. Researchers collect blood, saliva, stool, and lung fluid samples, along with regular lung function tests, to find early signs of lung inflammation (pneumonitis). The goal is to create a database that may help spot problems sooner, allowing faster treatment and better care for future patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors detect lung inflammation earlier in lung cancer patients, leading to quicker treatment and better outcomes.
What could go wrong: This is an observational study, not testing a new treatment. It may not find reliable early warning signs, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG NON-SMALL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG NON-SMALL CELL CARCINOMA

Contacts and locations

Locations

M D Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.